Lung Cancer | Specialty

NSCLC Immunotherapy: Transformation of Upfront Therapy

September 28th 2017

Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25th 2017

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

Immunotherapy Paradigm Continues to Evolve in NSCLC

September 24th 2017

Recent approval of immunotherapy in the first-line setting for treatment of patients with locally advanced and metastatic non–small cell lung cancer without driver mutations represents changes in care.

Dr. West on Lurbinectedin in SCLC

September 20th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.

Dr. Garassino on the PACIFIC Trial for NSCLC

September 20th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).

Dr. Besse on the Combination of Treatments for NSCLC

September 20th 2017

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non

Dr. Bauml Discusses the FLAURA Study in NSCLC

September 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

FDA Approves First Biosimilar for Cancer Treatment

September 14th 2017

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

Study Finds Hyperprogression After Immunotherapy in NSCLC Subset

September 14th 2017

Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.

Dr. West on the Significance of the PACIFIC Trial in NSCLC

September 13th 2017

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the significance of the PACIFIC trial in patients with non

Dr. Ramalingam on FLAURA Findings in EGFR-Mutant NSCLC

September 13th 2017

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Peters Discusses the FLAURA Trial for EGFR-Mutated NSCLC

September 11th 2017

Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non

Frontline Dabrafenib/Trametinib Effective for BRAF+ NSCLC

September 11th 2017

Frontline treatment with the combination of dabrafenib and trametinib showed promising clinical efficacy for patients with BRAF-mutant metastatic non–small cell lung cancer.

Enhanced Post-Surgery Surveillance Not Linked to Longer OS in NSCLC

September 10th 2017

Expanding surveillance after surgery for early-stage non–small cell lung cancer from chest x-ray to follow-up with PET-CT scan did not improve overall survival.

Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC

September 9th 2017

Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.

Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy

September 9th 2017

A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.

Nivolumab Past One Year Improves Progression-Free Survival in Pretreated NSCLC

September 9th 2017

Continuous treatment with nivolumab until disease progression was associated with superior progression-free survival compared with a 1-year fixed duration treatment for patients with previously treated advanced non-small cell lung cancer.

Durvalumab "Game-Changer" for Locally Advanced Lung Cancer

September 9th 2017

The PD-L1 inhibitor durvalumab improved median progression-free survival by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III lung cancer who had not progressed following chemoradiotherapy.

Frontline Osimertinib Doubles PFS for EGFR+ NSCLC

September 9th 2017

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Dr. Garon on Differences Between Antiangiogenic Agents in Lung Cancer

September 8th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.